Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.3K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.3K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.4K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Metastasis02:30

Metastasis

5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robotic-assisted versus laparoscopic esophageal hiatal hernia and anti-reflux surgery: A comprehensive systematic review and meta-analysis.

Hernia : the journal of hernias and abdominal wall surgery·2026
Same author

Proteogenomics of Hypertrophic Cardiomyopathy Reveals Subtype-Specific Therapy.

Circulation research·2026
Same author

Neural-tumor crosstalk in driving tumor metabolic reprogramming.

Biochimica et biophysica acta. Reviews on cancer·2026
Same author

Identification and validation of SPP1 as a prognostic biomarker in interstitial lung disease subtypes by single-cell sequencing.

Respiratory research·2026
Same author

A clinical-grade automated platform for the manufacturing of CAR-γδ T cells for immunotherapy.

Frontiers in immunology·2026
Same author

Microfluidic chips for decoding cancer-immune crosstalk in immunotherapy.

Frontiers in immunology·2026

Related Experiment Video

Updated: May 12, 2025

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

14.1K

METTL3 Promotes Cutaneous T-Cell Lymphoma Progression by Regulating ARHGEF12 Expression.

Lu Gan1, Yingqi Kong1, Haoze Shi1

  • 1Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China.

International Journal of Molecular Sciences
|May 7, 2025
PubMed
Summary
This summary is machine-generated.

N6-methyladenosine (m6A) RNA methylation regulates tumor growth. METTL3, an m6A methyltransferase, is upregulated in cutaneous T-cell lymphoma (CTCL) and drives its progression, suggesting METTL3 as a potential therapeutic target for CTCL.

Keywords:
ARHGEF12METTL3m6A

More Related Videos

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

6.7K
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.4K

Related Experiment Videos

Last Updated: May 12, 2025

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

14.1K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

6.7K
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • N6-methyladenosine (m6A) RNA methylation is a critical regulator in cancer development.
  • The role of METTL3, a key m6A methyltransferase, in cutaneous T-cell lymphoma (CTCL) remains underexplored.

Purpose of the Study:

  • To investigate the biological function and clinical significance of METTL3 in CTCL.
  • To determine the therapeutic potential of targeting METTL3 in CTCL.

Main Methods:

  • Quantitative real-time PCR to assess METTL3 expression in CTCL tissues.
  • siRNA-mediated knockdown of METTL3 in CTCL cell lines.
  • Western blotting to analyze protein levels.
  • RNA sequencing and m6A-specific immunoprecipitation to identify downstream targets.

Main Results:

  • METTL3 expression was significantly upregulated in CTCL patient samples compared to normal controls.
  • METTL3 knockdown inhibited CTCL cell proliferation, migration, and invasion in vitro.
  • METTL3 depletion led to decreased m6A modification of ARHGEF12 mRNA, promoting its degradation and suppressing tumor progression.
  • ARHGEF12 was identified as a direct downstream target of METTL3 in CTCL.

Conclusions:

  • METTL3 plays a crucial oncogenic role in CTCL progression.
  • METTL3-mediated regulation of ARHGEF12 is a key mechanism driving CTCL.
  • METTL3 represents a promising therapeutic target for the treatment of CTCL.